Most recently reported pay: $6.7M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities
Sep 16, 2026https://www.marketbeat.com/instant-alerts/event-amgen-highlights-maritide-imdelltra-pipeline-progress-and-growth-priorities-2026-09-16/sentiment +0.80
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Sep 7, 2026https://www.zacks.com/stock/news/2985908/amgen-shares-fall-as-novartis-pelacarsen-misses-phase-iii-study-goal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2985908sentiment -0.60
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Sep 7, 2026https://247wallst.com/investing/etf/2026/09/07/ibb-just-beat-the-sp-500-by-22-points-in-three-months-are-you-late-to-the-party/sentiment +0.40
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
Sep 2, 2026https://www.zacks.com/stock/news/2983706/j-j-faces-multiple-headwinds-can-the-healthcare-giant-sustain-growth?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2983706sentiment +0.40
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs
Sep 1, 2026https://247wallst.com/investing/2026/09/01/jim-cramer-this-little-talked-about-drug-could-target-the-biggest-market-of-all-time-aside-from-eli-lillys-glp-1-drugs/sentiment +0.90
BBH: Biotech's Next Growth Cycle Is Just Getting Started
Aug 24, 2026https://seekingalpha.com/article/4939474-bbh-biotechs-next-growth-cycle-is-just-getting-startedsentiment +0.80
